Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gossamer Bio Inc.

2.71
+0.20007.97%
Post-market: 2.710.0001+0.00%19:18 EST
Volume:2.79M
Turnover:7.49M
Market Cap:627.25M
PE:-3.94
High:2.77
Open:2.42
Low:2.42
Close:2.51
52wk High:3.60
52wk Low:0.6617
Shares:231.46M
Float Shares:183.82M
Volume Ratio:0.98
T/O Rate:1.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6874
EPS(LYR):-0.2499
ROE:-783.37%
ROA:-34.25%
PB:-7.62
PE(LYR):-10.85

Loading ...

Stock Track | Gossamer Bio Soars 5.30% Pre-Market as Oppenheimer Raises Price Target

Stock Track
·
Nov 10

BRIEF-Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Nov 08

Gossamer Bio Grants Stock Options to New Employees Under 2023 Inducement Plan

Reuters
·
Nov 08

Gossamer Bio Inc. to Present at Guggenheim Securities Healthcare Innovation Conference

Reuters
·
Nov 07

Gossamer Bio's Q3 net loss widens to $48.2 mln

Reuters
·
Nov 06

BRIEF-Gossamer Bio Q3 EPS USD -0.21

Reuters
·
Nov 06

Gossamer Bio Inc expected to post a loss of 19 cents a share - Earnings Preview

Reuters
·
Nov 04

EXPLAINER-How companies are steering IPO plans amid US government shutdown

Reuters
·
Oct 07

Wedbush Adjusts Gossamer Bio Price Target to $6 From $5, Maintains Outperform Rating

MT Newswires Live
·
Sep 25

Sector Update: Health Care Stocks Decline Premarket Thursday

MT Newswires Live
·
Sep 25

Gossamer Bio Issues 2.5M Shares for Merger Option, Plans Additional 1.5M Shares and Up to 6.7M in Milestone Stock Payments

Reuters
·
Sep 25

Respira Therapeutics Enters Into Agreement With Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira From Samsara Biocapital

THOMSON REUTERS
·
Sep 25

Press Release: Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Dow Jones
·
Sep 25

Gossamer Bio - Shareholders of Respira Eligible for Some Milestone Payments and High Single‑Digit Royalty on Potential Net Sales of Rt234

THOMSON REUTERS
·
Sep 25

Gossamer Bio Inc - IF Option Is Exercised, Gossamer Does Not Expect to Commence Clinical Trials of Rt234 Until at Least 2027

THOMSON REUTERS
·
Sep 25

Gossamer Bio Inc - to Issue 2.5 Mln Shares, 1.5 Mln More on Option Exercise

THOMSON REUTERS
·
Sep 25

Gossamer Bio Enters Into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, Rt234, an Inhaled, on‑Demand Vardenafil for Pulmonary Hypertension

THOMSON REUTERS
·
Sep 25

Gossamer Bio Unveils New Clinical Insights into Seralutinib's Efficacy for Pulmonary Hypertension at ERS Congress 2025

Reuters
·
Sep 22

Gossamer Bio Announces Presentations at the European Respiratory Society (Ers) Congress 2025

THOMSON REUTERS
·
Sep 22

Cantor says has reinforced conviction on Gossamer Bio ahead of data readout

TIPRANKS
·
Sep 11